Tazopip

# Tazopip (Piperacillin/Tazobactam) ## Overview - **Classification**: Extended-spectrum penicillin antibiotic + Beta-lactamase inhibitor. - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases. ## Primary Indications 1. **Nosocomial Pneumonia**: Moderate to severe hospital-acquired or ventilator-associated pneumonia. 2. **Complicated Intra-abdominal Infections**: Including appendicitis, peritonitis, abscesses. 3. **Complicated Skin and Skin Structure Infections**: Including cellulitis, abscesses, diabetic foot infections. 4. **Gynecologic Infections**: Postpartum endometritis, pelvic inflammatory disease. 5. **Febrile Neutropenia**: Empiric therapy for presumed bacterial infection in neutropenic patients. ## Adult Dosing ### Standard Dosing **Nosocomial Pneumonia** - **Dose**: **4.5 g** (piperacillin 4 g/tazobactam 0.5 g) - **Frequency**: Every **6 hours** (standard infusion) or every **8 hours** (extended infusion over 3-4 hours) - **Route**: Intravenous (IV) - **Duration**: 7-14 days, depending on infection. **Complicated Intra-abdominal, Skin/Soft Tissue, Gynecologic Infections** - **Dose**: **3.375 g** (piperacillin 3 g/tazobactam 0.375 g) - **Frequency**: Every **6 hours** - **Route**: Intravenous (IV) - **Duration**: 5-14 days, depending on infection. **Febrile Neutropenia** - **Dose**: **4.5 g** (piperacillin 4 g/tazobactam 0.5 g) - **Frequency**: Every **6 hours** - **Route**: Intravenous (IV) - **Duration**: Until resolution of fever or neutropenia. ### Dose Adjustments - **Renal Impairment**: Adjust based on CrCl. * CrCl 20-40 mL/min: **2.25 g IV q6h** OR **3.375 g IV q8h** for extended infusion. * CrCl <20 mL/min: **2.25 g IV q8h** OR **2.25 g IV q12h** for extended infusion. * Hemodialysis: **2.25 g IV q12h**; administer **0.75 g** after each dialysis session. - **Hepatic Impairment**: No specific adjustment recommended; use with caution. - **Elderly Patients**: Adjust based on renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **75 mg piperacillin/kg/dose** (total 84.375 mg/kg/dose of Tazopip). - **Frequency**: Every **6-8 hours** for age <7 days; every **4-6 hours** for age 7-28 days. - **Maximum**: Individualized, not firmly established. - **Special Notes**: Use with caution due to immature renal function and increased risk of seizures. ### Infants (1-9 months) - **Dose**: **80 mg piperacillin/kg/dose** (total 90 mg/kg/dose of Tazopip). - **Frequency**: Every **8 hours**. - **Maximum**: **4.5 g/dose**. ### Children (9 months - 12 years) **General Infections (e.g., intra-abdominal, skin/soft tissue, pneumonia)** - **Dose**: **80 mg piperacillin/kg/dose** (total 90 mg/kg/dose of Tazopip). - **Frequency**: Every **6-8 hours**. - **Maximum**: **4 g piperacillin/dose** (equivalent to **4.5 g Tazopip**). Total daily max **16 g piperacillin**. **Febrile Neutropenia** - **Dose**: **90 mg piperacillin/kg/dose** (total 101.25 mg/kg/dose of Tazopip). - **Frequency**: Every **6 hours**. - **Maximum**: **4 g piperacillin/dose** (equivalent to **4.5 g Tazopip**). Total daily max **18 g piperacillin**. ### Adolescents (13-18 years) - **Dose**: Generally follows **adult dosing** recommendations. - **Maximum**: **16-18 g piperacillin/day** (equivalent to **18-20.25 g Tazopip**). ## Safety Information ### Contraindications - **Absolute**: History of severe allergic reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins, cephalosporins, or other beta-lactamase inhibitors. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea. - **Common (1-10%)**: Nausea, vomiting, headache, rash, constipation, insomnia, pruritus. - **Serious but Rare**: Seizures (especially with renal impairment), Clostridioides difficile-associated diarrhea (CDAD), severe cutaneous adverse reactions (SCARs), anaphylaxis, thrombocytopenia, leukopenia. ### Key Drug Interactions - **Methotrexate**: May increase methotrexate levels and toxicity. Monitor methotrexate levels. - **Warfarin**: May prolong prothrombin time (PT)/INR. Monitor for bleeding. - **Vecuronium (and other NMBAs)**: Prolongs neuromuscular blockade. Monitor. - **Vancomycin**: Increased risk of acute kidney injury (AKI) when co-administered. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (SCr, CrCl), liver function tests (LFTs), complete blood count (CBC). - **During Treatment**: Monitor renal function (daily/every other day), CBC (weekly, especially for prolonged therapy), electrolytes (potassium), LFTs. - **Clinical Signs**: Monitor for allergic reactions (rash, dyspnea), signs of CDAD (severe diarrhea), neurological changes (seizures). ## Clinical Pearls - 💡 **Extended infusion (3-4 hours)** may improve clinical outcomes in critically ill patients by optimizing pharmacodynamics (T>MIC). - 💡 Administer standard infusion over **30 minutes IV**. - 💡 Higher risk of **acute kidney injury** when co-administered with vancomycin; monitor renal function closely. - 💡 Monitor for **leukopenia/neutropenia**, particularly with prolonged treatment courses (>10-14 days). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.